91 result(s) have been found!
| Accession | Name | Sequence | Source/Organism | Mechanism | Assay Type | Cell Line | Cancer Type | Activity |
|---|---|---|---|---|---|---|---|---|
| dbacp00301 | (cpm)-1285 | KNLWAAQRYGRELRRMSDEFEGSFKGL | BH3-only, Sensizers (BAD, HRK, Noxa) | Apoptosis inducing | Not specified | HL-60 | Various cancers | Not found |
| dbacp00352 | [C/U, G1K, L5Y, K8R]cGm | KURRYUYRQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HL-60 | Epithelial cancer | CC50 : 33.3 ±7.4 μM |
| dbacp00353 | [C/U, G1K, L5Y, K8R]cGm | KURRYUYRQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HL-60 | Chronic myeloid Leukemia | CC50 : 33.3 ±7.4 μM |
| dbacp00354 | [C/U, G1K, L5Y, K8R]cGm | KURRYUYRQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HL-60 | Gastric cancer | CC50 : 33.3 ±7.4 μM |
| dbacp00355 | [C/U, G1K, L5Y, K8R]cGm | KURRYUYRQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HL-60 | Breast cancer | CC50 : 33.3 ±7.4 μM |
| dbacp00356 | [C/U, G1K, L5Y, K8R]cGm | KURRYUYRQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HL-60 | Cervical cancer | CC50 : 33.3 ±7.4 μM |
| dbacp00392 | [C/U]cGm | GURRLUYKQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HL-60 | Epithelial cancer | CC50 : 38.5 ± 4.8 μM |
| dbacp00393 | [C/U]cGm | GURRLUYKQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HL-60 | Chronic myeloid Leukemia | CC50 : 38.5 ± 4.8 μM |
| dbacp00394 | [C/U]cGm | GURRLUYKQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HL-60 | Gastric cancer | CC50 : 38.5 ± 4.8 μM |
| dbacp00395 | [C/U]cGm | GURRLUYKQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HL-60 | Breast cancer | CC50 : 38.5 ± 4.8 μM |
| dbacp00396 | [C/U]cGm | GURRLUYKQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HL-60 | Cervical cancer | CC50 : 38.5 ± 4.8 μM |
| dbacp00470 | [G1K, K8R]cGm | KCRRLCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HL-60 | Epithelial cancer | CC50 : 9.0 ± 1.1μM |
| dbacp00471 | [G1K, K8R]cGm | KCRRLCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HL-60 | Chronic myeloid Leukemia | CC50 : 9.0 ± 1.1μM |
| dbacp00472 | [G1K, K8R]cGm | KCRRLCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HL-60 | Gastric cancer | CC50 : 9.0 ± 1.1μM |
| dbacp00473 | [G1K, K8R]cGm | KCRRLCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HL-60 | Breast cancer | CC50 : 9.0 ± 1.1μM |
| dbacp00474 | [G1K, K8R]cGm | KCRRLCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HL-60 | Cervical cancer | CC50 : 9.0 ± 1.1μM |
| dbacp00510 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HL-60 | Epithelial cancer | CC50 : 15.7 ±1.1μM |
| dbacp00511 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HL-60 | Chronic myeloid Leukemia | CC50 : 15.7 ±1.1μM |
| dbacp00512 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HL-60 | Gastric cancer | CC50 : 15.7 ±1.1μM |
| dbacp00513 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HL-60 | Breast cancer | CC50 : 15.7 ±1.1μM |
| dbacp00514 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HL-60 | Cervical cancer | CC50 : 15.7 ±1.1μM |
| dbacp00603 | [R4A, R18A]cGm | GCRALCYKQRCVTYCRGA | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HL-60 | Epithelial cancer | CC50 : 34.1 ± 3.9 μM |
| dbacp00604 | [R4A, R18A]cGm | GCRALCYKQRCVTYCRGA | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HL-60 | Chronic myeloid Leukemia | CC50 : 34.1 ± 3.9 μM |
| dbacp00605 | [R4A, R18A]cGm | GCRALCYKQRCVTYCRGA | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HL-60 | Gastric cancer | CC50 : 34.1 ± 3.9 μM |
| dbacp00606 | [R4A, R18A]cGm | GCRALCYKQRCVTYCRGA | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HL-60 | Breast cancer | CC50 : 34.1 ± 3.9 μM |
| dbacp00607 | [R4A, R18A]cGm | GCRALCYKQRCVTYCRGA | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HL-60 | Cervical cancer | CC50 : 34.1 ± 3.9 μM |
| dbacp00962 | ACL LAO L-amino acid oxidase(LAO) | ADSRNPLEEEFRETNYEEF | Venom base | Apoptosis inducing | HL-60 cell culture assay | HL-60 | Not specified | Not found |
| dbacp01371 | Aurein-3.2 | GLFDIVKKIAGHIASSI | Southern bell frog | Cell membrane disintegration | One-dose and five-dose assay | HL-60(TB) | Leukemia | IC50 : 4-5 μM |
| dbacp01458 | Bax 1 | STKKLSECLKRIGDELDSnM | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | HL-60 | Not specified | IC50 : 2.0 μmol/L |
| dbacp01462 | Bax 10 | KLSECLKRIGDELDS | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | HL-60 | Not specified | IC50 : > 500 μmol/L |
| dbacp01466 | Bax 11 | LSECLKRIGDELDSN | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | HL-60 | Not specified | IC50 : > 500 μmol/L |
| dbacp01470 | Bax 12 | STKKLECLKRIGDELDSnM | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | HL-60 | Not specified | IC50 : > 500 μmol/L |
| dbacp01474 | Bax 13 | STKKLCLKRIGDELDSnM | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | HL-60 | Not specified | IC50 : > 500 μmol/L |
| dbacp01478 | Bax 14 | STKKLLKRIGDELDSnM | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | HL-60 | Not specified | IC50 : > 500 μmol/L |
| dbacp01482 | Bax 15 | STKKLSECLGDELDSnM | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | HL-60 | Not specified | IC50 : > 500 μmol/L |
| dbacp01486 | Bax 16 | STKKLSECLKRIGDEL | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | HL-60 | Not specified | IC50 : 20 μmol/L |
| dbacp01490 | Bax 17 | TKKLSECLKRIGDEL | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | HL-60 | Not specified | IC50 : 79 μmol/L |
| dbacp01494 | Bax 18 | TKKLSECLKRIGDE | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | HL-60 | Not specified | IC50 : > 500 μmol/L |
| dbacp01498 | Bax 2 | AAKKLSECLKRIGDELDSnM | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | HL-60 | Not specified | IC50 : 2.3 μmol/L |
| dbacp01502 | Bax 3 | STKKLSECLKRIGDELDS | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | HL-60 | Not specified | IC50 : 18.3 μmol/L |
| dbacp01506 | Bax 4 | STKKLSECLKRIGDELDSM | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | HL-60 | Not specified | IC50 : 7.6 μmol/L |
| dbacp01510 | Bax 5 | STKKLSECLKRIGDELDM | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | HL-60 | Not specified | IC50 : 2.1 μmol/L |
| dbacp01514 | Bax 6 | STKKLSECLKRIGDELM | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | HL-60 | Not specified | IC50 : 8.0 μmol/L |
| dbacp01518 | Bax 7 | STKKLSECLKRIGDEM | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | HL-60 | Not specified | IC50 : 7.4 μmol/L |
| dbacp01522 | Bax 8 | STKKLSECLKRIGDM | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | HL-60 | Not specified | IC50 : > 500 μmol/L |
| dbacp01526 | Bax 9 | KKLSECLKRIGDELDSnM | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | HL-60 | Not specified | IC50 : 148.0 μmol/L |
| dbacp01990 | Buforin IIb | RAGLQFPVGRLLRRLLRRLLR | Histone H2A | Inducing mitochondria-dependent apoptosis | MTT/MTS assay | HL-60 | Leukemia cancer | IC50 : 11.3 µg/ml |
| dbacp02048 | Buforin Iib | RAGLQFPVGRLLRRLLRRLLR | Not found | Inducing apoptosis | MTT/MTS assay | HL-60 | Not specified | IC50 : 11.3 µg/ml |
| dbacp02318 | Cationic Amphiphilic | GIIKKIIIKKI | AMP | Membrane disruption | WST-1 assay | HL-60 | Pancreatic cancer | IC50 : >500 µM |
| dbacp02319 | Cationic Amphiphilic | GIIKKIIIKKIIIKKI | AMP | Membrane disruption | WST-1 assay | HL-60 | Pancreatic cancer | IC50 : 25 µM |
| dbacp02320 | Cationic Amphiphilic | GIIKKIIIKKIIIKKIIIKKI | AMP | Membrane disruption | WST-1 assay | HL-60 | Pancreatic cancer | IC50 : 10 µM |
| dbacp02478 | ChMAP-28 | GRFKRFRKKLKRLWHKVGPFVGPILHY | Domestic goat | Cause cell membrane permeability; Induce necrotic death | Cytotoxic Activity assay, Lactate dehydrogenase (LDH)-Releaseassay, MTT assay | HL-60 | Acute promyelocytic leukemia | IC50 : 3.39 ± 0.15 μM |
| dbacp02552 | Cpm-1285 | KNLWAAQRYGRELRRMSDEFEGSFKGL | BH3-only, Sensizers (BAD, HRK, Noxa) | Inducing apoptosis | Not specified | HL-60 | Not specified | IC50 : 130 nM |
| dbacp02554 | Cpm-1285m | KNLWAAQRYGREARRMSDEFEGSFKGL | BH3-only, Sensizers (BAD, HRK, Noxa) | Inducing apoptosis | Not specified | HL-60 | Not specified | Not found |
| dbacp03540 | L-amino-acid oxidase (BatroxLAAO) (LAO) (EC 1.4.3.2) | MNVFFTFSLLFLAALGSCADDRNPLEECFRETDYEEFLEIAKNGLSTTSNPKRVVIVGAGMSGLSAAYVLANAGHQVTVLEASERAGGRVKTYRNEKEGWYANLGPMRLPEKHRIVREYIRKFDLQLNEFSQENENAWYFIKNIRKRVGEVNKDPGVLEYPVKPSEVGKSAGQLYEESLQKAVEELRRTNCSYMLNKYDTYSTKEYLLKEGNLSPGAVDMIGDLLNEDSGYYVSFIESLKHDDIFAYEKRFDEIVGGMDKLPTSMYQAIQEKVHLNARVIKIQQDVKEVTVTYQTSEKETLSVTADYVIVCTTSRAARRIKFEPPLPPKKAHALRSVHYRSGTKIFLTCTKKFWEDDGIHGGKSTTDLPSRFIYYPNHNFPNGVGVIIAYGIGDDANYFQALDFEDCGDIVINDLSLIHQLPKEEIQAICRPSMIQRWSLDKYAMGGITTFTPYQFQHFSEALTAPVDRIYFAGEYTAQAHGWIDSTIKSGLRAARDVNRASEIKK | Common lancehead | Inducing apoptosis | MTT assay | HL-60 | Not found | Not found |
| dbacp03683 | Lasioglossin LL-III | VNWKKILGKIIKVVK | Broad-faced Furrow Bee | Cell membrane disintegration | XTT test | HL-60 | Not found | IC50 : 4.5 μM |
| dbacp04701 | mPep1 | RKAFRWAWRMLKKAAPSITCVR | Bovine lactoferrin (Lf-B) | Necrotic cell death by destroying cellular membrane structure; Apoptotic cell death | MTT/MTS assay | HL-60 | Skin cancer | IC50 :8 µM |
| dbacp04871 | NK-2 (Mammals, Animals) | KILRGVCKKIMRTFLRRISKDILTGKK | Mammal | Not specified | MTT assay | HL-60 | Not found | IC50 : 13.7 μM |
| dbacp04875 | NK-dpro (Derived from NK-2) | KILPGVCKKIMRPFLRRISKDILTGKK | Synthetic construct | Not specified | MTT assay | HL-60 | Not found | IC50 : 48.4 μM |
| dbacp04879 | NK-pro (Derived from NK-2) | KILRGVCKKIMRPFLRRISKDILTGKK | Synthetic construct | Not specified | MTT assay | HL-60 | Not found | IC50 : 26.1 μM |
| dbacp05245 | pep1 | FKCRRWQWRMKKLGAPSITCVR | Bovine lactoferrin (Lf-B) | Activating an apoptosis-inducing pathway | MTT/MTS assay | HL-60 | Prostate cancer | IC50 :77 µM |
| dbacp05247 | Pep27 | MRKEFHNVLSSGQLLADKRPARDYNRK | Pneumococcus | Apoptosis inducing | MTT/MTS assay | HL-60 | Leukemia cancer | IC50 : > 70 µM |
| dbacp05252 | Pep27 | MRKEFHNVLSSGQLLADKRPARDYNRK | Not found | Inducing apoptosis | MTT assay | HL-60 | Acute promyelocytic leukemia | IC50 : > 70 µM |
| dbacp05258 | Pep27 anal1 | MWKWFHNVLSSWQLLADKRPARDYNRK | Not found | Inducing apoptosis | MTT assay | HL-60 | Acute promyelocytic leukemia | IC50 : 53 µM |
| dbacp05263 | Pep27 anal2 | MWKWFHNVLSWWWLLADKRPARDYNRK | Not found | Inducing apoptosis | MTT assay | HL-60 | Acute promyelocytic leukemia | IC50 : 20 µM |
| dbacp05268 | Pep27 anal3 | MRKWFHNVLSSGQLLADKWPAWDYNRK | Not found | Inducing apoptosis | MTT assay | HL-60 | Acute promyelocytic leukemia | IC50 : 52 µM |
| dbacp05273 | Pep27 anal4 | MWKEFHNVLSSGQLLADKRWARWYNRW | Not found | Inducing apoptosis | MTT assay | HL-60 | Acute promyelocytic leukemia | IC50 : 51 µM |
| dbacp05278 | Pep27 anal5 | MWKWFHNVLSSGQLLADKWWAWWYNWW | Not found | Inducing apoptosis | MTT assay | HL-60 | Acute promyelocytic leukemia | IC50 : > 70 µM |
| dbacp05283 | Pep27anal1 | MWKWFHNVLSSWQLLADKRPARDYNRK | Pneumococcus | Apoptosis inducing | MTT/MTS assay | HL-60 | Leukemia cancer | IC50 : 53 µM |
| dbacp05288 | Pep27anal2 | MWKWFHNVLSWWWLLADKRPARDYNRK | Pneumococcus | Apoptosis inducing | MTT/MTS assay | HL-60 | Leukemia cancer | IC50 : 20 µM |
| dbacp05293 | Pep27anal3 | MRKWFHNVLSSGQLLADKWPAWDYNRK | Pneumococcus | Apoptosis inducing | MTT/MTS assay | HL-60 | Leukemia cancer | IC50 : 52 µM |
| dbacp05298 | Pep27anal4 | MWKEFHNVLSSGQLLADKRWARWYNRW | Pneumococcus | Apoptosis inducing | MTT/MTS assay | HL-60 | Leukemia cancer | IC50 : 51 µM |
| dbacp05303 | Pep27anal5 | MWKWFHNVLSSGQLLADKWWAWWYNWW | Pneumococcus | Apoptosis inducing | MTT/MTS assay | HL-60 | Leukemia cancer | IC50 : >70 µM |
| dbacp05434 | Peptide-1 | IELLQARGGC-Pem | Synthetic construct | Cell membrane disintegration | MTT/MTS assay | HL-60 | Leukemia cancer | IC50 : 2.17 µM |
| dbacp05436 | Peptide-2 | IELLQARGGC-Pem-GGRRRRRRRR | Synthetic construct | Cell membrane disintegration | MTT/MTS assay | HL-60 | Leukemia cancer | IC50 : 2.64 µM |
| dbacp05438 | Peptide-20 | CSSRTMHHC | Synthetic Peptide | Inducing apoptosis | MTT/MTS assay | HL-60 | Leukemia cancer | At 100 µM 90% viablity |
| dbacp05445 | Peptide-3 | RRRRRRRRGGC-Pem | Synthetic construct | Cell membrane disintegration | MTT/MTS assay | HL-60 | Leukemia cancer | IC50 : 6.24 µM |
| dbacp05597 | Polyphemusin III | RRGCFRVCYRGFCFQRCR | Atlantic horseshoe crab | Induce permeabilization of the cytoplasmic membrane | Trypan blue exclusion assay and Lactate dehydrogenase(LDH)-release assay | HL-60 | Human cervical cancer | IC50 : < 10 μM |
| dbacp06082 | Short α-helical peptide | GIIKKIIKKI | Alpha-helical proteins | Cell membrane disruption; Cell apoptosis | MTT/MTS assay | HL-60 | Leukemia cancer | 100% Cytotoxicity at 4µM approx. |
| dbacp06083 | Short α-helical peptide | GIIKKIIKKIIKKI | Alpha-helical proteins | Cell membrane disruption; Cell apoptosis | MTT/MTS assay | HL-60 | Leukemia cancer | 90% Cytotoxicity at 4µM approx. |
| dbacp06084 | Short α-helical peptide | GIIKKIIKKIIKKIIKKI | Alpha-helical proteins | Cell membrane disruption; Cell apoptosis | MTT/MTS assay | HL-60 | Leukemia cancer | 70% Cytotoxicity at 5µM approx. |
| dbacp06752 | Salamandrin - I | FAVWGCADYRGY | Salamandra salamandra | Pyroptosis mediated | MTT assay | HL-60 | Leukemia Cancer | IC50 = 27 µM |
| dbacp06753 | Salamandrin - I | FAVWGCADYRGY | Salamandra salamandra | Pyroptosis mediated | LDH leakage assay | HL-60 | Leukemia Cancer | Absorbance ~ 2 at 490 nm at 27 27 µM |
| dbacp06808 | [C/U, G1K, L5Y, K8R]cGm | KURRYUYRQRUVTYURGR | Synthetic Analogue of Gomesin | Cell membrane penetration | Resazurin dye assay | HL-60 | Leukemia Cancer | CC50 = 33.3 ±7.4μM |
| dbacp06814 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic Analogue of Gomesin | Cell membrane penetration | Resazurin dye assay | HL-60 | Leukemia Cancer | CC50 = 15.7 ±1.1μM |
| dbacp06824 | [C/U]cGm | GURRLUYKQRUVTYURGR | Synthetic Analogue of Gomesin | Cell membrane penetration | Resazurin dye assay | HL-60 | Leukemia Cancer | CC50 = 38.5 ± 4.8 μM |
| dbacp06830 | [G1K, K8R]cGm | KCRRLCYRQRCVTYCRGR | Synthetic Analogue of Gomesin | Cell membrane penetration | Resazurin dye assay | HL-60 | Leukemia Cancer | CC50 = 9.0 ± 1.1μM |
| dbacp06836 | [R4A, R18A]cGm | GCRALCYKQRCVTYCRGA | Synthetic Analogue of Gomesin | Cell membrane penetration | Resazurin dye assay | HL-60 | Leukemia Cancer | CC50 = 34.1 ± 3.9 μM |
| dbacp08378 | IDP-LS05 | RKRRNDLRSRFLALRDQ | Synthetic | Not Available | MTT/Alamamar-Blue/Hexosaminidase activity test | HL-60 | Leukemia Cancer | EC50 ~ 5 μM |
| dbacp08381 | IDP-LS13 | RKRRNDLRSRFLALRDQ | Synthetic | Not Available | MTT/Alamamar-Blue/Hexosaminidase activity test | HL-60 | Leukemia Cancer | EC50 ~ 7 μM |
| dbacp08426 | 5-2C | NYPQRPCRGDKGPDC | Synthetic | Not Available | MTT assay | HL-60 | Blood Cancer | IC50 = 1.111 μM |